BORA LIM

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
Address7200 CAMBRIDGE
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionBaylor College of Medicine
    DepartmentDuncan Cancer Center
    DivisionCancer Center


    Collapse ORNG Applications 
    Collapse Faculty Mentor
    Collapse Verify Publications

    Collapse Overview 

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Minussi DC, Nicholson MD, Ye H, Davis A, Wang K, Baker T, Tarabichi M, Sei E, Du H, Rabbani M, Peng C, Hu M, Bai S, Lin YW, Schalck A, Multani A, Ma J, McDonald TO, Casasent A, Barrera A, Chen H, Lim B, Arun B, Meric-Bernstam F, Van Loo P, Michor F, Navin NE. Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature. 2021 Apr; 592(7853):302-308. PMID: 33762732.
      Citations:    Fields:    
    2. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin SY. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021 May; 32(5):661-672. PMID: 33736924.
      Citations: 2     Fields:    
    3. Lim B. PD-L1 in Breast Cancer: The oad to the erfect iomarker is raught with ncertainty. J Natl Cancer Inst. 2021 Feb 01. PMID: 33523229.
      Citations:    Fields:    
    4. Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, Meas S, DeSnyder SM, Lim B, Valero V, Woodward W, Ueno NT, Kuerer H, Lucci A. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Jan 05. PMID: 33403525.
      Citations:    Fields:    
    5. Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 Feb; 26(2):e230-e240. PMID: 33140515.
      Citations:    Fields:    
    6. Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, Chen H, Sahin AA, Lim B. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS One. 2020; 15(11):e0241775. PMID: 33180796.
      Citations:    Fields:    Translation:Humans
    7. Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel). 2020 Oct 24; 12(11). PMID: 33114311.
      Citations:    
    8. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs. 2021 Apr; 39(2):509-515. PMID: 32984932.
      Citations: 1     Fields:    
    9. Li P, Lu M, Shi J, Gong Z, Hua L, Li Q, Lim B, Zhang XH, Chen X, Li S, Shultz LD, Ren G. Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. Nat Immunol. 2020 11; 21(11):1444-1455. PMID: 32958928.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    10. Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, Lim B, Ueno NT. Targeting Signaling Pathways in Inflammatory Breast Cancer. Cancers (Basel). 2020 Sep 01; 12(9). PMID: 32883032.
      Citations: 2     
    11. Winer A, Denlinger CS, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, Gallant JN, Wang EW, Kunkel M, Lim B, Harvey HA, Sivik J, Korzekwa K, Ruth K, White K, Cooper HS, Ross EA, Zhou L, El-Deiry WS. First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2021 Mar; 20(1):e43-e52. PMID: 32972830.
      Citations:    Fields:    
    12. Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Ann Surg Oncol. 2020 Nov; 27(12):4603-4612. PMID: 32710271.
      Citations: 1     Fields:    
    13. Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS One. 2020; 15(4):e0231953. PMID: 32353087.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    14. Lim B, Lin Y, Navin N. Advancing Cancer Research and Medicine with Single-Cell Genomics. Cancer Cell. 2020 04 13; 37(4):456-470. PMID: 32289270.
      Citations: 15     Fields:    Translation:Humans
    15. Milbury K, Weathers SP, Durrani S, Li Y, Whisenant M, Li J, Lim B, Weinberg JS, Kesler SR, Cohen L, Bruera E. Online Couple-Based Meditation Intervention for Patients With Primary or Metastatic Brain Tumors and Their Partners: Results of a Pilot Randomized Controlled Trial. J Pain Symptom Manage. 2020 06; 59(6):1260-1267. PMID: 32061834.
      Citations:    Fields:    
    16. Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist. 2020 06; 25(6):e909-e919. PMID: 32003919.
      Citations: 1     Fields:    
    17. Yennurajalingam S, Carmack C, Balachandran D, Eng C, Lim B, Delgado M, Guzman Gutierrez D, Raznahan M, Park M, Hess KR, Williams JL, Lu Z, Ochoa J, Bruera E. Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. BMJ Support Palliat Care. 2020 Jan 10. PMID: 31924662.
      Citations:    Fields:    
    18. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med. 2020 02; 9(3):1025-1032. PMID: 31849202.
      Citations: 3     Fields:    
    19. Lim B, Greer Y, Lipkowitz S, Takebe N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers (Basel). 2019 Jul 31; 11(8). PMID: 31370269.
      Citations: 9     
    20. Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol. 2019 10; 92:32-38. PMID: 31351155.
      Citations: 2     Fields:    Translation:Humans
    21. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jul; 176(1):251. PMID: 30982934.
      Citations:    Fields:    
    22. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers (Basel). 2019 May 24; 11(5). PMID: 31137625.
      Citations: 19     
    23. Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer. 2019 06; 120(12):1105-1112. PMID: 31097774.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    24. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174. PMID: 31005169.
      Citations:    Fields:    Translation:Humans
    25. Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351. PMID: 30826934.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    26. Kang S, Kim EH, Hwang JE, Shin JH, Jeong YS, Yim SY, Joo EW, Eun YG, Lee DJ, Sohn BH, Lee SH, Lim B, Lee JS. Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer. Biochem Biophys Res Commun. 2019 03 26; 511(1):185-191. PMID: 30777332.
      Citations: 3     Fields:    Translation:HumansCells
    27. Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS One. 2018; 13(10):e0204513. PMID: 30312311.
      Citations: 10     Fields:    Translation:HumansCells
    28. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol. 2018 09 01; 4(9):1207-1213. PMID: 29879283.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    29. Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018 08; 18(8):485-499. PMID: 29703913.
      Citations: 45     Fields:    Translation:HumansCells
    30. Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Author Correction: Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018 Aug; 18(8):526. PMID: 29748602.
      Citations: 2     Fields:    
    31. Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288. PMID: 30077429.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    32. Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat. 2018 Sep; 171(2):501-511. PMID: 29915946.
      Citations: 2     Fields:    Translation:Humans
    33. Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am. 2018 Aug; 98(4):787-800. PMID: 30005774.
      Citations: 7     Fields:    Translation:Humans
    34. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447. PMID: 29721054.
      Citations: 11     
    35. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. 2018 06 01; 124(11):2299-2305. PMID: 29579338.
      Citations: 3     Fields:    Translation:Humans
    36. Le-Petross HT, Lim B. Role of MR Imaging in Neoadjuvant Therapy Monitoring. Magn Reson Imaging Clin N Am. 2018 May; 26(2):207-220. PMID: 29622126.
      Citations: 3     Fields:    Translation:Humans
    37. He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol. 2018 Feb 17; 149(3):253-261. PMID: 29425258.
      Citations: 5     Fields:    Translation:Humans
    38. Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. Oncotarget. 2018 Jan 23; 9(6):6872-6882. PMID: 29467936.
      Citations: 1     Fields:    
    39. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017 Oct 01; 28(10):2420-2428. PMID: 28961844.
      Citations: 20     Fields:    Translation:Humans
    40. Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One. 2017; 12(9):e0185231. PMID: 28957377.
      Citations: 8     Fields:    Translation:HumansCells
    41. Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. JAMA Oncol. 2017 Sep 01; 3(9):1266-1273. PMID: 28301631.
      Citations: 41     Fields:    Translation:HumansCells
    42. Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT. Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Dec; 166(3):819-832. PMID: 28831670.
      Citations: 5     Fields:    Translation:HumansCells
    43. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol. 2017 Jul; 9(7):493-511. PMID: 28717401.
      Citations: 16     
    44. Sato N, Wakabayashi M, Nakatsuji M, Kashiwagura H, Shimoji N, Sakamoto S, Ishida A, Lee J, Lim B, Ueno NT, Ishihara H, Inui T. MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochem Biophys Res Commun. 2017 08 05; 489(4):484-489. PMID: 28576487.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    45. Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B, Ueno NT. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4780-4792. PMID: 28465444.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    46. Ralff MD, Kline CLB, Küçükkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Mol Cancer Ther. 2017 07; 16(7):1290-1298. PMID: 28424227.
      Citations: 10     Translation:HumansAnimalsCells
    47. Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017 04; 18(4):e228-e232. PMID: 28368261.
      Citations: 25     Fields:    Translation:Humans
    48. Matsuda N, Lim B, Wang X, Ueno NT. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. Expert Opin Investig Drugs. 2017 Apr; 26(4):463-479. PMID: 28271910.
      Citations: 17     Fields:    Translation:HumansAnimals
    49. Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272. PMID: 28243898.
      Citations: 11     Fields:    Translation:Humans
    50. Lim B, Hortobagyi GN. Current challenges of metastatic breast cancer. Cancer Metastasis Rev. 2016 12; 35(4):495-514. PMID: 27933405.
      Citations: 16     Fields:    Translation:Humans
    51. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 08; 7(45):74380-74392. PMID: 27602582.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    52. Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget. 2016 Jan 26; 7(4):3662-76. PMID: 26695546.
      Citations: 10     Fields:    Translation:HumansCells
    53. Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, Lim B, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. J Cancer. 2015; 6(12):1306-19. PMID: 26640591.
      Citations: 8     
    54. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015 May 30; 6(15):12890-908. PMID: 25973541.
      Citations: 34     Fields:    Translation:Humans
    55. Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets. 2015; 19(9):1171-85. PMID: 26004811.
      Citations: 35     Fields:    Translation:HumansAnimals
    56. Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15; 75(8):1668-74. PMID: 25681273.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    57. Ma Y, Hao S, Wang S, Zhao Y, Lim B, Lei M, Spector DJ, El-Deiry WS, Zheng SY, Zhu J. A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. Mol Cancer Ther. 2015 Mar; 14(3):835-43. PMID: 25589497.
      Citations: 7     Translation:HumansCells
    58. El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biol Ther. 2015; 16(12):1726-37. PMID: 26553611.
      Citations: 26     Translation:Humans
    59. Lim B, Jiang Y. Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer "The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease". Curr Clin Pharmacol. 2015; 10(4):267-78. PMID: 26548904.
      Citations: 1     Fields:    Translation:Humans
    60. Brennan M, Lim B. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. Adv Exp Med Biol. 2015; 867:327-37. PMID: 26530375.
      Citations: 2     Fields:    Translation:Humans
    61. Lee HJ, Song IH, Seo AN, Lim B, Kim JY, Lee JJ, Park IA, Shin J, Yu JH, Ahn JH, Gong G. Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy. Ann Surg Oncol. 2015 Feb; 22(2):392-400. PMID: 25192679.
      Citations: 2     Fields:    Translation:Humans
    62. Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, Lim B. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Res. 2014; 3:198. PMID: 25400908.
      Citations: 9     Fields:    
    63. Lee HJ, Park IA, Park SY, Seo AN, Lim B, Chai Y, Song IH, Kim NE, Kim JY, Yu JH, Ahn JH, Gong G. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 2014 Jun; 145(3):615-23. PMID: 24820412.
      Citations: 12     Fields:    Translation:Humans
    64. Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther. 2013 Aug; 14(8):711-9. PMID: 23792567.
      Citations: 4     Translation:Humans
    65. Lim B, Cream LV, Harvey HA. Update on clinical trials: genetic targets in breast cancer. Adv Exp Med Biol. 2013; 779:35-54. PMID: 23288634.
      Citations: 3     Fields:    Translation:Humans
    LIM's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (194)
    Explore
    _
    Co-Authors (85)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _